Psyence Biomedical Ltd
NASDAQ:PBM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Psyence Biomedical Ltd
Cash from Financing Activities
Psyence Biomedical Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Psyence Biomedical Ltd
NASDAQ:PBM
|
Cash from Financing Activities
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Cash from Financing Activities
-$742m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Cash from Financing Activities
$117.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
6%
|
CAGR 10-Years
83%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Cash from Financing Activities
CA$5.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Financing Activities
CA$10.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Cash from Financing Activities
-$40.5m
|
CAGR 3-Years
-177%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
Psyence Biomedical Ltd
Glance View
Psyence Biomedical Ltd is a CA-based company operating in industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
See Also
What is Psyence Biomedical Ltd's Cash from Financing Activities?
Cash from Financing Activities
0
USD
Based on the financial report for Dec 31, 2022, Psyence Biomedical Ltd's Cash from Financing Activities amounts to 0 USD.
